MACUSTAR

Intermediate AMD: development of novel clinical endpoints for clinical trials in patients with a regulatory and patient access intention
MACUSTAR logo

FACTS & FIGURES

Start Date
End Date
Grant agreement number
116076

Contributions
IMI Funding
8 025 000
EFPIA in kind
8 067 500
Other
0
Total Cost16 092 500

Summary

People with dry age-related macular degeneration (AMD) gradually lose their central vision, usually in both eyes. It is already a leading cause of blindness worldwide, and as the population ages, the number of cases is likely to rise. There is currently no effective treatment for dry AMD. One barrier to the development of new treatments is the lack of tests capable of determining the effectiveness of treatments under development. Put simply, current tests do not detect all of the sight problems experienced by people with earlier stages of the disease (e.g. intermediate AMD).

The goal of the MACUSTAR project is to develop and validate tests that are capable of accurately detecting subtle changes in the disease over time. The project will follow more than 700 AMD patients over 3 years through tests including state-of-the-art imaging techniques and vision testing, as well as patient-reported outcome measures that capture the impact of the disease on patients’ quality of life. The hope is that these methods will prove capable of detecting changes in the patients’ disease. The team also hopes to shed new light on visual impairment in intermediate AMD and its progression, as well as the risk factors that cause the disease to progress faster in some patients than others.

By developing and validating new methods to study disease progression in dry AMD, the overall goal of MACUSTAR is to help drug development and make clinical trials of potential treatments more efficient.

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • Novartis Pharma AG, Basel, Switzerland
Universities, research organisations, public bodies, non-profit groups
  • AIBILI - Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal
  • Carl Zeiss Meditec AG, Jena, Germany
  • City, University of London, London, United Kingdom
  • European Clinical Research Infrastructure Network (ECRIN-ERIC), Paris, France
  • Fondation Voir et Entendre, Paris, France
  • Stichting Katholieke Universiteit / Radboud university medical center, Nijmegen, Netherlands
  • The University of Sheffield, Sheffield, United Kingdom
  • Universitaetsklinikum Bonn, Bonn, Germany
  • University College London, London, United Kingdom
Patient organisations
  • Moorfields Eye Hospital Nhs Foundation Trust, London, United Kingdom
Third parties
  • Centre Hospitalier National D'Ophtalmologie Des Quinze-Vingts, Paris, France
  • Universidade Nova De Lisboa, Lisboa, Portugal

CONTACT

Project coordinator
Frank Holz
Universitaetsklinikum Bonn
Frank.Holz[at]ukb.uni-bonn.de